APW
BDRX

Allied Private Wealth’s Biodexa Pharmaceuticals BDRX Stock Holding History

Allied Private Wealth’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27K Buy
+489
New +$1.65K ﹤0.01% 786

Other funds holding BDRX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Allied Private Wealth's BDRX Position: Q2 2026 in Review

Allied Private Wealth opened a new position in Biodexa Pharmaceuticals (BDRX) in Q2 2026: 489 shares worth $1.27K. The stake represents ﹤0.01% of the portfolio and ranks #786 among its holdings.

8 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • Allied Private Wealth held 489 shares of Biodexa Pharmaceuticals worth $1.27K as of Q2 2026.
  • Biodexa Pharmaceuticals was a new Allied Private Wealth position in Q2 2026.
  • Biodexa Pharmaceuticals made up ﹤0.01% of Allied Private Wealth's portfolio in Q2 2026, its #786 holding.
  • 8 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on Allied Private Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.